

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OIPF IAPTA
DEC 04 2006
PATENT & TRADEMARK OFFICE
RE APPLICATION OF: AN ET AL.

APPLICATION No.: 10/588,883

INTERNATIONAL FILING DATE: FEBRUARY 7, 2005

FOR: METHODS FOR ISOLATION OF TRIPTOLIDE
COMPOUNDS FROM *TRIPTYERYGIUM WILFORDII*

EXAMINER: TO BE ASSIGNED

ART UNIT: 1623

CONF. NO: 4457

**Information Disclosure Statement Within Three Months of
Application Filing or Before First Action – 37 C.F.R. § 1.97(b)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the National Stage of an International Application or before the mailing date of a first Office Action on the merits or before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under 37 CFR §1.114, whichever occurs last (37 CFR 1.97(b)(4)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

B. Cited Information

- ☒ Copies of references 1-18 are issued patent(s) and published application(s) and are not included (see C.F.R. § 1.98(a)(2)(ii)).
- ☒ Copies of references 19-22 are enclosed.

C. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional

information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

D. Fee Payment


No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

E. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,
Perkins Coie LLP


Date: December 1, 2006



Brian S. Boyer
Registration No. 52,643

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)					COMPLETE IF KNOWN	
			Application Number	10/588,883	Confirmation Number	4457
			Filing Date	August 9, 2006		
			First Named Inventor	An <i>et al.</i>		
			Group Art Unit	1623		
			Examiner Name	Unassigned		
			Attorney Docket No.	62497-8004.US00		
Sheet	1	of				

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1.	4,005,108		Kupchan <i>et al.</i>	1/25/77	
	2.	5,192,817		Takaishi <i>et al.</i>	3/9/93	
	3.	5,430,054		Qian <i>et al.</i>	7/4/95	
	4.	5,468,772		Xu <i>et al.</i>	11/21/95	
	5.	5,580,562		Lipsky <i>et al.</i>	12/3/96	
	6.	5,648,376		Strobel <i>et al.</i>	7/15/97	
	7.	5,663,335		Qi <i>et al.</i>	9/2/97	
	8.	5,759,550		Weidmann <i>et al.</i>	6/2/98	
	9.	5,843,452		Weidmann <i>et al.</i>	12/1/98	
	10.	5,962,516		Qi <i>et al.</i>	10/5/99	
	11.	6,150,539		Musser	11/21/00	
	12.	6,294,546		Rosen <i>et al.</i>	9/25/01	
	13.	6,537,984		Rosen <i>et al.</i>	3/25/03	
	14.	6,548,537		Dai <i>et al.</i>	4/15/03	
	15.	6,569,893	B2	Dai <i>et al.</i>	5/27/03	
	16.	6,599,499		Rosen <i>et al.</i>	7/29/03	
	17.	6,620,843		Fidler <i>et al.</i>	9/16/03	
	18.	2004-0018260		Ren <i>et al.</i>	1/29/04	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
	19.	CN	CN 1317248	A	Fujian Province Medical Research Institute	10/17/01		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/588,883
				Confirmation Number	4457
				Filing Date	August 9, 2006
				First Named Inventor	An <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket No.	62497-8004.US00

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	20.	Cheng <i>et al.</i> , <i>Chinese J. of Pharmaceuticals</i> , 21(10):435-436 (1990)	
	21.	Kupchan <i>et al.</i> , <i>J. Am. Chem. Soc.</i> , 94(20):7194-7195 (1972).	
	22.	Zhang <i>et al.</i> , <i>ACTA Pharmaceutica Sinica</i> , 28(2):110-115 (1993).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	